FDA classifies Medtronic's Octopus Nuvo Tissue Stabilizer recall as Class I

NewsGuard 100/100 Score

Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use. The resulting potential hazards are that fragments of the component could fall into the patient's chest cavity and/or damage the heart tissue. Medtronic has received two reports of device failure occurring during patient use, which required retrieval of device fragments from the surgical wound; neither event resulted in permanent impairment or death.

Healthcare facilities should immediately discontinue use of the device and return all unused Octopus Nuvo Tissue Stabilizer devices to Medtronic. No action is required of patients, as any adverse event related to the disposable device would have occurred at the time of surgery.

All Octopus Nuvo Tissue Stabilizer devices are affected; no other models in the Octopus family of products are affected by this recall.

Five-hundred and seventy-one devices have been distributed to healthcare facilities in the U.S., Europe and Canada. All affected healthcare facilities have been notified, and Medtronic is in the process of working with them to retrieve all remaining devices. The FDA has been apprised of this action.

Physicians and healthcare facilities can direct questions to their Medtronic representative or contact the CardioVascular Lifeline for technical services, Monday through Friday during business hours, at 1-877-526-7890. Any adverse reactions experienced with the use of this product, and/or quality problems also should be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by Fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Racial disparities found in delayed COVID-19 testing among healthcare workers